natgillin/translations-raw huggingface dataset:
The main measure of effectiveness was the proportion of patients who responded to treatment and whose brain tumour shrank by at least half after six months of treatment.
Glavno mjerilo djelotvornosti bio je omjer bolesnika koji su reagirali na liječenje i čiji se tumor mozga smanjio za najmanje pola nakon šest mjeseci liječenja.
The main measure of effectiveness was the proportion of patients who responded to treatment and whose kidney tumour shrank by at least half.
Glavno mjerilo djelotvornosti bio je omjer bolesnika koji su reagirali na liječenje i čiji se tumor bubrega smanjio za najmanje pola.
The main measure of effectiveness was the proportion of patients who responded to treatment, defined as no evidence of disease and recovery of blood cell counts, within a month of starting Atriance treatment.
Glavna mjera djelotvornosti bio je udio bolesnika koji su odgovorili na terapiju, defirano kao izostanak dokaza bolesti i oporavak broja krvnih stanica unutar mjesec dana od početka terapije lijekom Atriance.
The main measure of effectiveness was the proportion of patients whose cortisol level in the urine normalised after six months.
Glavna mjera djelotvornosti bio je omjer bolesnika čije su razine kortizola u urinu normalizirane nakon šest mjeseci.
The main measure of effectiveness was the proportion of patients whose HIV-1 levels in the blood (viral loads) had fallen below a defined level.
Glavna mjera djelotvornosti bio je udio bolesnika u kojih se razina virusa HIV-1 u krvi (virusno opterećenje) smanjila ispod utvrđene razine.
The main measure of effectiveness was the reduction in number of patients who needed a blood transfusion.
Glavna mjera učinkovitosti bilo je smanjenje broja bolesnika koji su trebali transfuziju krvi.
The main measure of effectiveness was the reduction in the levels of HIV in the blood (viral load) after 16 weeks; a third study involved 566 patients who had not taken HIV treatment before and compared Isentress with efavirenz (another anti-HIV medicine).
Glavna mjera djelotvornosti bilo je smanjenje razina HIV-a u krvi (virusno opterećenje) nakon 16 tjedana; treće je ispitivanje obuhvatilo 566 bolesnika koji nisu prethodno primali terapiju protiv HIV-a te je usporedilo lijek Isentress s efavirenzom (drugim lijekom za liječenje HIV-a).
The main measure of effectiveness was the reduction in the number of fleas and ticks in the infested dogs during the 3 months after receiving treatment.
Glavna mjera djelotvornosti bilo je smanjenje broja buha i krpelja u infestiranih pasa tijekom 3 mjeseca nakon primjene terapije.
The main measure of effectiveness was the reduction in the number of patients with low vitamin D levels after 15 weeks.
Glavna mjera djelotvornosti bilo je smanjenje broja bolesnica s niskim koncentracijama vitamina D nakon 15 tjedana.
The main measure of effectiveness was the reduction in the number of patients with low vitamin D levels after 15 weeks.
Glavna mjera djelotvornosti bilo je smanjenje broja bolesnica s niskim razinama vitamina D nakon 15 tjedana.
The main measure of effectiveness was the risk of clinical failure (the patients’ disease getting worse).
Glavna mjera djelotvornosti bila je rizik od kliničkog neuspjeha (pogoršanje bolesti).
The main measure of effectiveness was the time spent in the ‘off’ state during the day, as recorded in patients’ diaries.
Glavno mjerilo djelotvornosti bilo je vrijeme provedeno u lošem stanju tijekom dana, kako je zabilježeno u dnevnicima bolesnika.
The main measure of effectiveness was the time until death due to disease of the heart or blood vessels, or hospitalisation due to worsening heart failure.
Glavna mjera djelotvornosti bilo je vrijeme do smrti uzrokovane bolešću srca ili krvnih žila ili hospitalizacijom zbog pogoršanja zatajenja srca.
The main measure of effectiveness was whether Nimenrix was as good as the comparator vaccines at stimulating an immune response against the four types of N. meningitidis polysaccharides showing an ability to kill the bacteria.
Glavno mjerilo djelotvornosti bila je ocjena toga je li lijek Nimenrix jednako djelotvoran kao usporedno cjepivo pri stimulaciji imunosnog odgovora protiv četiriju tipova polisaharida iz bakterije N. meningitidis koji pokazuju sposobnost ubijanja bakterija.
The main measure of the immune response was the level of antibodies against PCV2 in the piglets’ blood.
Glavna mjera imunosnog odgovora je razina antitijela za PCV2 u krvi prasadi.
The main measure to indicate effectiveness of the medicine was the improvement in x-ray appearance of the wrists and knee joints of patients before and after treatment with Strensiq.
Glavna mjera indikacije učinkovitosti lijeka bilo je poboljšanje u rendgenskom pojavljivanju zglobova ruke i koljena prije i nakon terapije lijekom Strensiq.
The main measures of effectiveness for the two studies were the change in pain intensity as measured on a pain scale and the number of patients who responded to treatment after ten minutes.
Glavna mjera djelotvornosti u ova dva ispitivanja bila je promjena u intenzitetu boli kako je izmjereno na skali boli i broj bolesnika koji su odgovorili na liječenje nakon deset minuta.
The main measures of effectiveness were average daily weight gain during the finishing period, the level of PCV2 in the blood and a score for the severity of damage (lesions) to the lung.
Glavne mjere djelotvornosti bile su prosječna dnevna težina dobivena tijekom razdoblja završnog tovljenja, razina PCV2 u krvi i rezultat na ljestvici oštećenja (lezija) na plućima.
The main measures of effectiveness were based on muscle strength and the reduction in patients’ disability.
Glavna mjera djelotvornosti temeljila se na mišićnoj snazi i smanjenju oštećenja u bolesnika.
The main measures of effectiveness were based on the number of patients who had 20 or 50% reductions in the number and severity of symptoms after 14 or 24 weeks.
Glavne mjere djelotvornosti temeljile su se na broju bolesnika koji su imali 20 %-tno ili 50 %-tno smanjenje broja i ozbiljnosti simptoma nakon 14 tjedana ili 24 tjedna.
The main measures of effectiveness were based on the number of strokes or clotting events that occurred during treatment.
Glavna mjera djelotvornosti temeljena je na broju moždanih udara ili ugrušaka koji su nastupili tijekom liječenja.
The main measures of effectiveness were how well the defects had healed after one year and the change in the patients’ Knee Injury and Osteoarthritis Outcome Score (KOOS) after one and three years of treatment.
Glavne mjere djelotvornosti bile su stupanj zacijeljenosti oštećenja nakon jedne godine i promjena u rezultatu ishoda mjerenja nakon oštećenje koljena i osteoartritisa (Knee Injury and Osteoarthritis Outcome Score - KOOS) nakon jedne i tri godina liječenja.
The main measures of effectiveness were improvement in symptom scores and in the level of amyloid A in the blood (another marker of inflammation).
Glavno mjerilo djelotvornosti bilo je poboljšanje rezultata simptoma i koncentracija amiloida A u krvi (drugi marker upale).
The main measures of effectiveness were lung function (‘forced vital capacity’, the maximum amount of air the patient could breathe out), and the distance the patients could walk in six minutes, which measures the combined effects of the illness on the heart, lungs, joints and other organs.
Glavne mjere djelotvornosti bile su funkcija pluća („forsirani vitalni kapacitet”, tj. maksimalna količina zraka koju bolesnik može izdahnuti) i udaljenost koju je bolesnik mogao prehodati u šest minuta, čime se mjere kombinirani učinci bolesti na srce, pluća, zglobove i ostale organe.
The main measures of effectiveness were pain intensity (measured on a scale from 0 to 100) 3 days after taking the medicine, as well as the time to a first new attack of gouty arthritis.
Glavno mjerilo djelotvornosti bio je intenzitet boli (izmjeren na skali od 0 do 100) 3 dana nakon uzimanja lijeka kao i vrijeme do novog napadaja uričnog artritisa.
The main measures of effectiveness were progression-free survival and overall survival (the length of time the patients lived).
Glavna mjera djelotvornosti bilo je preživljenje bez progresije bolesti i ukupno preživljavanje (koliko su dugo bolesnici živjeli).
The main measures of effectiveness were reductions in heavy bleeding and associated anaemia, as well as the size of the fibroids.
Glavna mjera djelotvornosti bilo je manje obilno krvarenje i povezana anemija, kao i veličina fibroida.
The main measures of effectiveness were respiratory and depression scores as well as body temperature.
Glavna mjerila učinkovitosti bili su rezultati u odnosu na dišni sustav i depresiju te tjelesna temperatura.
The main measures of effectiveness were the change in platelet count and the number of patients who achieved ‘platelet count normalisation’ and ‘haematological normalisation’ (their levels of platelets and lactate dehydrogenase, an enzyme normally found in red blood cells, were within normal levels).
Glavno mjerilo djelotvornosti bila je promjena u broju trombocita i broju bolesnika koji su postigli „normalizaciju broja trombocita” i „hematološku normalizaciju” (njihove razine trombocita i laktat dehidrogenaze, enzima koji se obično nalazi u crvenim krvnim stanicama, bile su unutar granica normalnih vrijednosti).
The main measures of effectiveness were the levels of antibodies against the flu virus in the patients’ blood before vaccination, on the day of the second injection (day 22), and 21 days later (day 43).
Glavne mjere djelotvornosti bile su razine protutijela na virus gripe u krvi bolesnika prije cijepljenja na dan druge injekcije (dan 22) te 21 dan nakon toga (dan 43).
The main measures of effectiveness were the levels of HIV in the blood (viral load) and the number of CD4 T-cells in the blood (CD4 cell count).
Glavno mjerilo djelotvornosti bile su koncentracije HIV-a u krvi (virusno opterećenje) i broj CD4 T- stanica u krvi (broj CD4 stanica).
The main measures of effectiveness were the number of patients who had at least a 20% reduction in the number and severity of symptoms after 12 weeks and a reduction in the worsening of joint damage after 24weeks.
Glavna mjera djelotvornosti bio je broj bolesnika u kojih je zabilježeno najmanje 20 %-tno smanjenje broja i težine simptoma nakon 12 tjedana te smanjenje pogoršanja oštećenja zglobova nakon 24 tjedna.
The main measures of effectiveness were the number of patients who had at least a 20% reduction in the number and severity of symptoms after 24 weeks and a reduction in the worsening of joint damage as seen on X-rays.
Glavna mjera djelotvornosti bio je broj bolesnika u kojih je zabilježeno najmanje 20 %- tno smanjenje broja i težine simptoma nakon 24 tjedna te smanjenje pogoršanja oštećenja zglobova, što je uočeno na rendgenskim snimkama.
The main measures of effectiveness were the number of patients whose bowels opened within four hours of the first dose, and the percentage of injections that were successful in producing a bowel movement.
Glavne mjere djelotvornosti bile su broj bolesnika čija su se crijeva otvorila unutar četiri sata od prve doze, kao i postotak injekcija koje su bile uspješne u pokretanju crijeva.
The main measures of effectiveness were the number of patients whose cancer responded to treatment, how long it took for the disease to progress, how long the patients remained disease-free or how long they survived.
Glavna mjera djelotvornosti bio je broj bolesnika čiji je rak odgovorio na terapiju, koliko je bilo potrebno do razvoja bolesti, koliko se dugo bolest u bolesnika nije vratila, odnosno koliko su dugo bolesnici preživjeli.
The main measures of effectiveness were the number of patients whose level of haemoglobin (a protein found in red blood cells) remained above their individual target level, and the number of red blood cell transfusions that the patients needed during the first 26 weeks of treatment.
Glavno mjerilo djelotvornosti bio je broj bolesnika čija se razina hemoglobina (proteina koji se nalazi u crvenim krvnim stanicama) zadržala iznad njihove individualne ciljne razine, te broj transfuzija crvenih krvnih stanica koje su bolesnicima bile potrebne tijekom prvih 26 tjedana liječenja.
The main measures of effectiveness were the number of patients with myeloablation and ‘engraftment’ (the time for the transplanted stem cells to begin growing and for white blood cells to return to higher levels).
Glavna mjera djelotvornosti bio je broj bolesnika s mijeloablacijom i „primanje presatka” (vrijeme potrebno da transplantirane matične stranice počnu rasti, a bijele krvne stanice vrate u više razine).
The main measures of effectiveness were the numbers of patients who achieved ‘thrombotic microangiopathy event-free’ status (they did not have a decrease of over 25% in platelet count after starting Soliris and did not require plasma exchange or infusion, or dialysis) and the number of patients who achieved haematological normalisation while receiving Soliris.
Glavno mjerilo djelotvornosti bio je broj bolesnika koji su postigli status „bez događaja trombotične mikroangiopatije” (nakon početka liječenja lijekom Soliris nisu imali smanjenje broja trombocita veće od 25 % te im nije bila potrebna zamjena plazme, infuzija niti dijaliza), te broj bolesnika koji je postigao hematološku normalizaciju prilikom terapije lijekom Soliris.
The main measures of effectiveness were the reduction in symptoms of arthritis after treatment, as well as physical function (the ability to carry out everyday tasks) and the amount of damage to the joints (assessed using X-rays).
Glavna mjera djelotvornosti bilo je smanjenje simptoma artritisa nakon terapije kao i fizička funkcija (sposobnost izvršavanja svakodnevnih poslova) i težina oštećenja zglobova (ocijenjeno rendgenskim zračenjem).
The main metabolic pathway for tegafur is through conversion to 5-FU via CYP2A6 in the liver, whereas gimeracil was stable in human liver homogenate (S9 fraction) with adenosine 3’-phosphate 5'-phosphosulfphate lithium salt (PAPS; a co-factor for sulfotransferase) or nicotinamide adenine dinucleotide phosphate (NADPH).
Glavni put metabolizma tegafura je kroz konverziju u 5-FU pomoću CYP2A6 u jetri, dok je gimeracil stabilan u ljudskom homogenatu jetre (S9 frakcija) s litijevom soli adenozin 3'-fosfat-5'-fosfosulfata (PAPS; ko-faktor sulfotransferaze) ili nikotinamid adenin dinukleotid fosfatom (NADP).
The main metabolic pathway for tegafur is through conversion to 5-FU via CYP2A6 in the liver, whereas gimeracil was stable in human liver homogenate (S9 fraction) with adenosine 3’-phosphate 5'-phosphosulfphate lithium salt (PAPS; a co-factor for sulfotransferase) or nicotinamide adenine dinucleotide phosphate (NADPH).
Glavni put metabolizma tegafura je kroz konverziju u 5-FU pomoću CYP2A6 u jetri, dok je gimeracil stabilan u ljudskom homogenatu jetre (S9 frakcija) sa litijevom soli adenozin 3'-fosfat-5'-fosfosulfata (PAPS; ko-faktor sulfotransferaze) ili nikotinamid adenin dinukleotid fosfatom (NADP).
The main metabolic pathways in humans were identified as oxidation by aldehyde oxidase, demethylation via CYP3A4, glutathione conjugation with elimination of the O-aryl group (chlorbenzyl moiety), and combinations of these pathways followed by further biotransformations (e.g., glucuronidation, hydrolysis of the glutathione moiety, degradation of the cysteine moiety, and intramolecular rearrangement of the cysteinylglycine and cysteine conjugates with subsequent dimerisation).
Kao glavni metabolički putevi u ljudi, utvrđene su oksidacija aldehid oksidazom, demetilacija putem CYP3A4, konjugacija s glutationom uz eliminaciju O-arilne skupine (klorbenzilna skupina) i kombinacija ovih puteva nakon čega slijedi daljnja biotransformacija (npr. glukuronidacija, hidroliza glutationske skupine, razgradnja cisteinske skupine i intramolekularno premještanje cisteinilglicina i konjugata cisteina daljnjom dimerizacijom).
The main metabolic pathways in humans were identified as oxidation by aldehyde oxidase, demethylation via CYP3A4, glutathione conjugation with elimination of the O-aryl group (chlorbenzyl moiety), and combinations of these pathways followed by further biotransformations (e.g., glucuronidation, hydrolysis of the glutathione moiety, degradation of the cysteine moiety, and intramolecular rearrangement of the cysteinylglycine and cysteine conjugates with subsequent dimerisation).
Kao glavni metabolički putevi u ljudi, utvrđene su oksidacija aldehid oksidazom, demetilacija putem CYP3A4, konjugacija s glutationom uz eliminaciju O-arilne skupine (klorbenzilni dio) i kombinacija ovih puteva nakon čega slijedi daljnja biotransformacija (npr. glukuronidacija, hidroliza glutationskog dijela, razgradnja cisteinskog dijela i intramolekularno premještanje cisteinilglicina i konjugata cisteina daljnjom dimerizacijom).
The main metabolite in plasma, the glucuronide conjugate of silodosin (KMD-3213G), that has been shown to be active in vitro, has an extended half-life (approximately 24 hours) and reaches plasma concentrations approximately four times higher than those of silodosin.
Glavni metabolit u plazmi, konjugat silodozina s glukuronidom (KMD-3213G) koji se pokazao djelatan in vitro, ima produljeni poluvijek (približno 24 sata) i postiže koncentracije u plazmi približno četiri puta veće od onih koje postiže silodozin.
The main metabolite is characterised as toltrazuril sulfone.
Osnovni metabolit je toltrazuril sulfon.
The main metabolite M1 is approximately 10 times less potent than atosiban in inhibiting oxytocin- induced uterine contractions in vitro.
Čini se da je glavni metabolit M1 otprilike 10 puta manje potentan od atosibana u inhibiciji kontrakcija maternice uzrokovanih oksitocinom in vitro.
The main metabolite M1 is approximately 10 times less potent than atosiban in inhibiting oxytocin-induced uterine contractions in vitro.
Glavni metabolit M1 je otprilike 10 puta manje potentan od atosibana u inhibiciji kontrakcija maternice uzrokovanih oksitocinom in vitro.
The main metabolites found in humans result from hydroxylation of the isopropyl side-chain, either on the methine carbon, or one of the methyl groups; activity of the main metabolites is about 5–6 and 3 times less potent than nateglinide, respectively.
Glavni metaboliti koji se nalaze u ljudi rezultat su hidroksilacije postraničnog lanca izopropila, ili na metinski ugljik, ili na jednu od metilnih grupa; aktivnost glavnih metabolita je oko 5-6 odnosno 3 puta manje snažna od one nateglinida.
The main molecular target of zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase.
Glavni molekulami cilj zoledronatne kiseline u osteoklastu je enzim farnezil pirofosfat sintaza.
The main objective of the follow-up study was to confirm the status of thyroid remnant ablation by using Thyrogen-stimulated radioiodine static neck imaging after a median follow-up of 3.7 years (range 3.4 to 4.4 years) following radioiodine ablation.
Glavni cilj praćenja bio je potvrditi stanje ablacije ostatnog tkiva štitnjače uz pomoć statičke radiojodne scintigrafije vrata stimulirane lijekom Thyrogen, nakon medijana praćenja od 3,7 godina (raspon od 3,4 do 4,4 godine) po radiojodnoj ablaciji.
The main pathway of metabolism is hydrolysis of the carboxylamide group to the pharmacologically inactive acid derivative CGP 47292.
Glavni metabolički put je hidroliza karboksilamidne skupine, čime nastaje farmakološki neaktivan kiseli derivat CGP 47292.
The main pharmacokinetic parameters are shown in the following table.
Glavni farmakokinetički parametri prikazani su sljedećoj tablici.
The main reason for treatment withdrawal for patients with high tumour burden during treatment cycle 1 in the lenalidomide arm was adverse events, 7/11 (64%).
Glavni razlog te obustave liječenja u bolesnika s velikim opterećenjem tumorskom masom tijekom 1. ciklusa u skupini liječenoj lenalidomidom bili su štetni događaji; 7/11 (64%).
The main risk factors for hyperkalaemia to be considered are:
Glavni faktori rizika za hiperkalemiju koji se moraju razmotriti su:
The main risk factors for hyperkalaemia to be considered are:
Glavni faktori rizika za hiperkalijemiju koji se moraju razmotriti su:
The main risk factors for hyperkalaemia to be considered are:
Glavni rizični faktori za hiperkalijemiju koje je potrebno razmotriti su:
The main route of elimination for 6–mercaptopurine is by metabolism.
Glavni put eliminacije 6-merkaptopurina je metabolizmom.
The main signs of the illness include mild signs of flu such as headache or fever, feeling very tired, dark urine, pale stools (faeces), yellow skin or eyes (jaundice).
Glavni znakovi bolesti uključuju blage znakove gripe poput glavobolje ili vrućice, osjećaja izrazitog umora, taman urin, svijetla stolica (feces), žuta koža ili bjeloočnice (žutica).
The main studies compared insulin glargine 100 units/ml given once a day at bedtime with human insulin NPH (an intermediate-acting insulin) given once or twice a day.
Glavna ispitivanja usporedila su inzulin glargin od 100 jedinica/ml koji se primjenjivao jednom na dan u vrijeme odlaska na počinak s ljudskim inzulinom NPH (kao srednje djelujućim inzulinom) koji se primjenjivao jednom ili dvaput na dan.
The main study of Foclivia included 486 healthy subjects (a third of whom were over the age of 60) and compared the ability of two doses of Foclivia to trigger the production of antibodies (immunogenicity).
Glavno ispitivanje na lijeku Foclivia uključivalo je 486 zdravih ispitanika (od kojih je trećina bila starija od 60 godina) i uspoređivalo je sposobnost dvije doze da potakne nastanak protutijela (imunogeničnost).
The main study showed that adding Empliciti to lenalidomide and dexamethasone can delay the worsening of multiple myeloma and improve response rates in patients whose disease had come back or did not respond to previous treatment.
Glavno ispitivanje pokazalo je da dodavanje lijeka Empliciti lenalidomidu i deksametazonu može odložiti pogoršanje multiplog mijeloma i poboljšati stope odgovora na liječenje u bolesnika kod kojih se bolest vratila ili u bolesnika koji nisu pozitivno reagirali na prethodnu terapiju.
The main symptoms of IBS-D include:
Glavni simptomi IBS-D-a uključuju:
The main target organs of toxicity in dogs are the gastrointestinal tract, the haematopoetic system, the kidney and the liver.
Glavni ciljni organi toksičnosti u pasa su probavni sustav, hematopoetski sustav, bubreg i jetra.
The main target organs of toxicity include the gastrointestinal tract, bone marrow, gonads and musculoskeletal system.
Glavni organi pogođeni toksičnošću uključuju gastrointestinalni trakt, koštanu srž, gonade i mišićno- koštani sustav.
The maintenance dose should not exceed 7.5 mg twice daily.
Doza održavanje ne smije prelaziti 7,5 mg dva puta na dan.
The maintenance dose: Once your red blood cells reach an acceptable level, the dose is reduced to half of the dose used to correct the anaemia.
Doza održavanja: Kad broj crvenih krvnih stanica dosegne zadovoljavajuću razinu, doza se smanjuje na polovicu doze korištene za korekciju anemije.
The maintenance of the effect has not been evaluated.
Trajanje učinka nije ocijenjeno.
The maintenance studies showed that long-term treatment with Rapamune was effective in helping the new kidney to survive, with an improvement in how well the new kidney worked and an improvement in blood pressure when ciclosporin treatment was stopped.
Ispitivanja tijekom terapije održavanja pokazala su da je dugoročna terapija lijekom Rapamune učinkovita u pomaganju preživljenja novog bubrega, uz poboljšanje funkcije novog bubrega i poboljšanje krvnoga tlaka nakon što je terapija ciklosporinom završena.
The major active metabolite is the N-desmethylated derivative (S 18982) with an exposure about 40% of that of the parent compound.
Glavni je aktivni metabolit N-desmetilirani derivat (S 18982) s koncentracijom oko 40% koncentracije roditeljske tvari.